Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10260499 | 1.00 | PARP1 (0.59) | PARP1TNK1 | |
| SCHEMBL10261489 | 0.90 | PARP1 (0.47) | PARP1TNK1 | |
| SCHEMBL533003 | 0.87 | PARP1 (0.56) | PARP1TNK1 | |
| SCHEMBL10262284 | 0.86 | PARP1 (0.74) | PARP1 | |
| SCHEMBL10261950 | 0.85 | PARP1 (0.58) | PARP1 | |
| SCHEMBL531922 | 0.85 | PARP1 (0.77) | PARP1TNK1 | |
| SCHEMBL532110 | 0.84 | PARP1 (0.62) | PARP1 | |
| SCHEMBL532663 | 0.83 | PARP1 (0.78) | PARP1TNK1 | |
| SCHEMBL531937 | 0.83 | PARP1 (0.78) | PARP1TNK1 | |
| SCHEMBL10262037 | 0.78 | PARP1 (0.44) | PARP1TNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885TNK1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.